1306729-46-3

Upstream product

• 497-18-7 carbonodihydrazide 
• 3153-44-4 4-(4-methoxy-phenyl)-4-oxo-butyric acid 

Downstream Products

• 1273319-46-2 C₁₉H₁₇N₅O₂S 
• 1273319-47-3 C₁₉H₁₆ClN₅O₂S 
• 1273319-48-4 6-(4-methoxyphenyl)-2-[4-(4-methylphenyl)-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]-4,5-dihydropyridazin-3(2H)-one 
• 1363389-11-0 6-(4-methoxyphenyl)-2-[4-(3-methylphenyl)-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]-4,5-dihydropyridazin-3(2H)-one 
• 1363389-10-9 6-(4-methoxyphenyl)-2-[4-(4-bromophenyl)-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]-4,5-dihydropyridazin-3(2H)-one 

Relevant academic research and scientific papers

Triazole incorporated pyridazinones as a new class of antihypertensive agents: Design, synthesis and in vivo screening

A number of 6-(substituted phenyl)-2-(4-substituted phenyl-5-thioxo-4,5- dihydro-1H-1,2,4-triazol-3-yl)-4,5-dihydropyridazin-3(2H)-one derivatives were designed and synthesized by a sequence of reactions starting from respective aryl hydrocarbons. The final compounds (4a-4u) were evaluated for antihypertensive activities by non-invasive method using Tail Cuff method. The compounds 4e, 4i and 4k showed appreciable antihypertensive activity comparable with that of standard hydralazine and propranolol.